Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America

PURE study design: A new registry of patients with moderate to severe chronic plaqUe psoRiasis in Canada and Latin AmErica (LACan)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2016.02.1026 ◽

2016 ◽

Vol 74 (5) ◽

pp. AB265

Keyword(s):

Latin America ◽

Study Design ◽

Plaque Psoriasis ◽

Secukinumab-treated patients in the PURE registry (Patients with Moderate to Severe Chronic Plaque Psoriasis in Latin America and Canada): 12-month follow-up data

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.1020 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB257

Keyword(s):

Latin America ◽

Plaque Psoriasis ◽

Real-world safety of secukinumab in patients with moderate to severe chronic plaque psoriasis in Latin America and Canada: Results from the PURE registry

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.959 ◽

2018 ◽

Vol 79 (3) ◽

pp. AB241

Keyword(s):

Latin America ◽

Real World ◽

Plaque Psoriasis ◽

Severe Chronic Plaque Psoriasis Increases Arterial Stiffness Risk

Skin & Allergy News ◽

10.1016/s0037-6337(08)70558-8 ◽

2008 ◽

Vol 39 (8) ◽

pp. 30

Author(s):

BRUCE JANCIN

Keyword(s):

Arterial Stiffness ◽

Plaque Psoriasis ◽

A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.28 ◽

2017 ◽

Vol 1 ◽

pp. s29

Author(s):

Andrew Blauvelt ◽

Joseph F Fowler, Jr. ◽

Ellen Schuck ◽

Julia Jauch ◽

Heike Woehling ◽

...

Keyword(s):

Multicenter Study ◽

Plaque Psoriasis ◽

Double Blind

Abstract Not Available

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

SKIN The Journal of Cutaneous Medicine ◽

10.25251/skin.1.supp.11 ◽

2017 ◽

Vol 1 ◽

pp. s12

Author(s):

Andrew Blauvelt ◽

Craig Leonardi ◽

Claus Zachariae ◽

Russel Burge ◽

Terri Ridenour ◽

...

Keyword(s):

Plaque Psoriasis ◽

Phase 2 ◽

Open Label ◽

Phase 2 Study ◽

Health Related

Abstract Not Available

Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis

Case Medical Research ◽

10.31525/ct1-nct03849404 ◽

2019 ◽

Author(s):

Keyword(s):

Plaque Psoriasis ◽

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis

Case Medical Research ◽

10.31525/ct1-nct03922607 ◽

2019 ◽

Author(s):

Keyword(s):

Healthy Volunteers ◽

Plaque Psoriasis ◽

Faculty Opinions recommendation of Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1164520.626285 ◽

2009 ◽

Cited By ~ 1

Author(s):

Joel Gelfand

Keyword(s):

Clinical Trial ◽

Weight Loss ◽

Plaque Psoriasis ◽

Low Dose ◽

Obese Patients ◽

Randomized Controlled ◽

Cyclosporine Therapy

Faculty Opinions recommendation of Efficacy and safety of itolizumab, a novel anti-CD6 monoclonal antibody, in patients with moderate to severe chronic plaque psoriasis: results of a double-blind, randomized, placebo-controlled, phase-III study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.718340215.793493941 ◽

2014 ◽

Author(s):

Kamran Ghoreschi ◽

Sebastian Volc

Keyword(s):

Monoclonal Antibody ◽

Plaque Psoriasis ◽

Phase Iii ◽

Efficacy And Safety ◽

Double Blind ◽

Phase Iii Study